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Identification of a DYRK1A 
Inhibitor that Induces Degradation 
of the Target Kinase using Co-
chaperone CDC37 fused with 
Luciferase nanoKAZ
Rie Sonamoto1,2, Isao Kii1,†, Yuka Koike1,†, Yuto Sumida3,‡, Tomoe Kato-Sumida3,‡, 
Yukiko Okuno4, Takamitsu Hosoya3 & Masatoshi Hagiwara1
The protein kinase family includes attractive targets for drug development. Methods for screening 
of kinase inhibitors remain largely limited to in vitro catalytic assays. It has been shown that 
ATP-competitive inhibitors antagonize interaction between the target kinase and kinase-specific 
co-chaperone CDC37 in living cells. Here we show a cell-based method to screen kinase inhibitors 
using fusion protein of CDC37 with a mutated catalytic 19-kDa component of Oplophorus luciferase, 
nanoKAZ (CDC37-nanoKAZ). A dual-specificity kinase DYRK1A, an importance of which has been 
highlighted in Alzheimer’s disease, was targeted in this study. We established 293T cells stably 
expressing CDC37-nanoKAZ, and analyzed interaction between CDC37-nanoKAZ and DYRK1A. 
We revealed that DYRK1A interacted with CDC37-nanoKAZ. Importantly, point mutations that 
affect autophosphorylation strengthened the interaction, thus improving signal/noise ratio of the 
interaction relative to non-specific binding of CDC37-nanoKAZ. This high signal/noise ratio enabled 
screening of chemical library that resulted in identification of a potent inhibitor of DYRK1A, 
named CaNDY. CaNDY induced selective degradation of DYRK1A, and inhibited catalytic activity 
of recombinant DYRK1A with IC50 value of 7.9 nM by competing with ATP. This method based on a 
mutant target kinase and a bioluminescence-eliciting co-chaperone CDC37 could be applicable to 
evaluation and development of inhibitors targeting other kinases.
Dysregulation of protein kinase activity is implicated in many pathological conditions, which makes pro-
tein kinases attractive targets for drug development. Dual-specificity tyrosine-phosphorylation-regulated 
1Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Yoshida-
Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. 2Laboratory of Functional Biology, Graduate School of Biostudies, 
Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. 3Laboratory of Chemical Bioscience, 
Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, 
Chiyoda-ku, Tokyo 101-0062, Japan. 4Medical Research Support Center, Graduate School of Medicine, Kyoto 
University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. †Current address: Pathophysiological and 
Health Science Team, Imaging Application Group, Division of Bio-Function Dynamics Imaging, RIKEN Center for 
Life Science Technologies, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan. ‡Current 
address: Chemical Biology Team, Imaging Chemistry Group, Division of Bio-Function Dynamics Imaging, RIKEN 
Center for Life Science Technologies, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan. 
Correspondence and requests for materials should be addressed to I.K. (email: isao.kii@riken.jp) or M.H. (email: 
hagiwara.masatoshi.8c@kyoto-u.ac.jp)
Received: 18 December 2014
Accepted: 07 July 2015
Published: 03 August 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:12728 | DOi: 10.1038/srep12728
kinase 1A (DYRK1A), the importance of which has been highlighted by its proposed relationship with 
early-onset Alzheimer’s disease1–3, is a potential target for drug development4. In a previous study, we 
developed a synthetic small molecule, INDY, that potently suppressed the kinase activity of DYRK1A in 
an in vitro kinase assay using recombinant DYRK1A protein5.
Kinase-specific co-chaperone CDC37 binds to heat shock protein 90 (HSP90) and client proteins 
simultaneously, facilitating their interaction6–9. Taipale et al. developed a quantitative high-throughput 
assay to assess interaction between these chaperones and client protein kinases using CDC37 and HSP90β 
fused with Renilla luciferase10, and demonstrated a strong correlation between CDC37::kinase and 
HSP90β ::kinase interactions. Stabilization of kinase domain of ABL, SRC, and EGF receptor (EGFR) by 
inhibitors decreased the HSP90β interaction in living cells10,11. Polier et al. showed that ATP-competitive 
inhibitors of B-RAF, ErbB2 and EGFRG719S directly antagonize the CDC37 interaction with target kinases 
in vitro12. Disruption of HSP90β association and degradation of c-Kit and ErbB2 kinases also occurs after 
treatment with kinase inhibitors13,14. Collectively, these studies suggest that the CDC37/HSP90 inter-
action with client kinases is sensitive to inhibitors targeting the kinases. Therefore, the CDC37/HSP90 
interaction assay could be available for screening of kinase inhibitors, instead of conventional in vitro 
kinase assay.
In this study, we developed a cell-based method to screen inhibitors of DYRK1A using fusion 
protein of CDC37 with a mutated catalytic 19-kDa component of Oplophorus luciferase, nanoKAZ 
(CDC37-nanoKAZ), by modifying the previously reported system10,11. Using this assay, we revealed that 
DYRK1A interacted with this chaperone. Furthermore, we found that mutations that affected catalytic 
activity of DYRK1A enhanced the CDC37 interaction with DYRK1A, which improved signal/noise ratio 
of the interaction relative to non-specific binding of CDC37-nanoKAZ, and enabled screening of chem-
ical library. Using this system, we examined an original synthetic chemical library, and found a small 
molecule that acts as an antagonist of the CDC37 interaction with DYRK1A.
Results
Treatment with a HSP90 inhibitor decreased the level of DYRK1A protein. To investigate 
whether DYRK1A is a client kinase of the CDC37/HSP90 system, we used a HSP90 inhibitor, gan-
etespib. 293T cells were transiently transfected with an expression vector of 3xFLAG-tagged DYRK1A 
(3xFLAG-DYRK1A). At 24 h after transfection, the cells were treated with ganetespib for the indicated 
time (0–8 h). Total cell lysates were collected and subjected to SDS-PAGE followed by Western blot 
analysis. Ganetespib decreased the DYRK1A level compared with the DMSO control (Fig. 1), indicating 
that stabilization of DYRK1A requires HSP90 activity. This result suggests that DYRK1A is a CDC37/
HSP90 client kinase.
Development of 293T cells expressing CDC37-nanoKAZ. To assess the CDC37 interaction 
with DYRK1A quantitatively, we developed an expression vector of CDC37 fused with nanoKAZ, a 
mutated catalytic 19-kDa component of Oplophorus luciferase15,16. The structure of CDC37-nanoKAZ is 
shown in Fig.  2a. Codon-optimized nanoKAZ was fused to the carboxyl-terminus of CDC37, because 
carboxyl-terminal tagging of CDC37 did not significantly affect its function10,11. 293T cells were tran-
siently transfected with the CDC37-nanoKAZ vector. At 48 h after transfection, total cell lysates were 
collected. Endogenous CDC37 was detected in Western blot analysis, along with a slower migrating band 
for the exogenous CDC37-nanoKAZ fusion protein (Fig. 2b). An antibody against nanoKAZ also recog-
nized CDC37-nanoKAZ (Fig. 2b). The luminescence intensity for CDC37-nanoKAZ in total cell lysate 
determined using its substrate, bis-coelenterazine, had a glow luminescence pattern (Supporting Figure 
S1a), as previously reported in nanoKAZ16. We then established stable 293T cell lines that expressed 
CDC37-nanoKAZ or nanoKAZ.
Figure 1. Ganetespib, a HSP90 inhibitor, decreases the DYRK1A protein level. 293T cells were transiently 
transfected with an expression vector for 3xFLAG-DYRK1A. At 24 h after transfection, the cells were treated 
with ganetespib (100 nM) and collected 0 and 8 h after treatment. Total cell lysates were subjected to SDS-
PAGE followed by Western blot analysis using antibodies against FLAG and GAPDH. In the control group 
(DMSO), expression of 3xFLAG-DYRK1A increased at 8 h compared to 0 h, and ganetespib suppressed this 
increase of 3xFLAG-DYRK1A.
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Mutations that affect autophosphorylation of DYRK1A strengthen the interaction with 
CDC37-nanoKAZ. Although the interaction between DYRK1A and CDC37/HSP90 had not been 
demonstrated yet, DYRK4 was categorized as a strong client kinase of the CDC37/HSP90 system10. To 
examine whether CDC37-nanoKAZ works as a reporter to detect the CDC37 interaction with its client 
kinase, we investigated interaction of CDC37-nanoKAZ with DYRK1A and DYRK4. The 293T cells stably 
expressing CDC37-nanoKAZ were transiently transfected with expression vectors for 3xFLAG-DYRK1A 
and 3xFLAG-DYRK4 in a 96-well plate. An expression vector for EGFP was also transfected as a neg-
ative control. Two days after transfection, the cells were lysed and cleared cell lysates were incubated 
in a 96-well plate coated with antibody against FLAG peptide. After binding at 4 °C for 3 h followed by 
extensive wash, bis-coelenterazine was injected into the wells and the luminescence kinetics was meas-
ured. The values for the initial luminescence intensity (Imax) were processed statistically. The amounts 
Figure 2. Interaction of DYRK1A with CDC37-nanoKAZ. (a) Structure of the CDC37-nanoKAZ protein. 
CDC37 and nanoKAZ is fused in-frame with a glycine-serine linker. (b) Expression of CDC37-nanoKAZ 
protein in transfected 293T cells. CDC37-nanoKAZ was detected with antibodies against CDC37 or 
nanoKAZ. GAPDH was detected as an internal control. (c) Interactions of 3xFLAG-DYRK1A and 3xFLAG-
DYRK4 with CDC37-nanoKAZ. Luminescence intensities of CDC37-nanoKAZ associated with 3xFLAG-
DYRK1A and 3xFLAG-DYRK4 proteins, which were bound on 96-well plates coated with antibody against 
FLAG, are shown as fold-changes relative to that with EGFP (luminescence due to non-specific binding of 
CDC37-nanoKAZ). Bar graphs show means ± SD, ***p < 0.001 (n = 8). (d) Cartoon illustrating the structure 
of 3xFLAG-DYRK1A, in which the mutations used in this study and the CDC37 consensus binding site 
are shown. (e) Interactions of intact and mutated DYRK1A proteins with CDC37-nanoKAZ. Luminescence 
intensities of CDC37-nanoKAZ associated with 3xFLAG-DYRK1A proteins are shown as fold-changes 
relative to that with EGFP. Bar graphs show means ± SD, **p < 0.01 (n = 5).
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of 3xFLAG-DYRK1A and 3xFLAG-DYRK4 bound on the antibody-coated well were quantified with a 
horseradish peroxidase (HRP) conjugated antibody against FLAG. The levels of bound proteins were 
almost the same (within ± 2.0%) between samples (Supporting Figure S1b).
Significant increases of the luminescence signal in the transfection of either 3xFLAG-DYRK1A or 
3xFLAG-DYRK4 with CDC37-nanoKAZ were detected (Fig.  2c), compared with EGFP (luminescence 
caused by non-specific binding of CDC37-nanoKAZ), indicating that CDC37-nanoKAZ functions as 
luminescence reporter to detect the CDC37 interaction with DYRK family kinases. 3xFLAG-DYRK4 
interacted with CDC37-nanoKAZ 102-fold more strongly than 3xFLAG-DYRK1A (Fig. 2c), suggesting 
that DYRK1A is a weak client kinase compared with DYRK4. We next examined the interaction of 
CDC37-nanoKAZ with DYRK1A harboring substitution mutations. The mutation sites are shown in 
Fig.  2d. Interestingly, a 3xFLAG-tagged kinase-dead mutant of DYRK1A, in which Lys188 was substi-
tuted to Arg (K188R), interacted with CDC37-nanoKAZ 17-fold more strongly than intact DYRK1A 
(Fig. 2e), whereas the amounts of bound proteins were similar (Supporting Figure S1c). Lys188 is essen-
tially involved in orienting ATP for catalysis17, and thus the K188R mutant lost its kinase activity17. The 
strengthened interaction of the K188R mutant suggests that the kinase activity is involved in the CDC37 
interaction.
To further confirm whether the kinase activity is involved in the CDC37 interaction, an expression 
vector for 3xFLAG-DYRK1A harboring two mutations in the activation loop was prepared, in which 
Tyr319 and Tyr321 were substituted to Phe (Y319F/Y321F). The requirement for phosphorylation of 
these tyrosine residues remains uncertain17–20, but the Y319F/Y321F mutant lost its kinase activity17,21,22. 
3xFLAG-DYRK1A (Y319F/Y321F) interacted with CDC37-nanoKAZ 8.0-fold more strongly than intact 
DYRK1A (Fig.  2e). These results suggest that inactive forms of DYRK1A interact with CDC37 more 
strongly than the active form.
The kinase-dead mutants (K188R and Y319F/Y321F) were unable to catalyze autophosphorylation, in 
addition to substrate phosphorylation. If autophosphorylation affects the CDC37 interaction, the auto-
phosphorylation sites around the CDC37-interacting glycine-rich loop would be involved in the interac-
tion (see Fig. 2d). Therefore, we prepared expression vectors of 3xFLAG-DYRK1A harboring mutations 
at Tyr111 (Y111F), Tyr145 and Tyr147 (Y145F/Y147F), and Tyr159 (Y159F), which are the reported 
autophosphorylation sites17,20, and examined the interaction with CDC37-nanoKAZ. 3xFLAG-DYRK1A 
(Y159F) interacted with CDC37-nanoKAZ 8.4-fold more strongly than intact DYRK1A (Fig.  2e). The 
other mutants, Y111F and Y145F/Y147F, interacted with CDC37-nanoKAZ 1.4- and 2.4-fold more 
strongly than intact DYRK1A, respectively (Fig. 2e). The amounts of bound these mutant proteins were 
similar to that of wild-type (Supporting Figure S1c). Furthermore, the intact and mutated DYRK1A 
proteins did not interact with nanoKAZ (Supporting Figure S1d). These results indicate a possibility that 
the interaction of DYRK1A with CDC37 is regulated by autophosphorylation.
DYRK1A interacts with HSP90β fused with nanoKAZ. CDC37 binds to HSP90 and client kinases 
simultaneously, and facilitates their interaction6–9. We therefore examined the interaction between 
DYRK1A and HSP90β . The structure of nanoKAZ-HSP90β is shown in Fig. 3a. Codon-optimized nano-
KAZ was fused to the amino-terminus of HSP90β . 293T cell line stably expressing nanoKAZ-HSP90β 
was established. Expression of nanoKAZ-HSP90β was confirmed by Western blot analysis (Fig. 3b). To 
measure the interaction, the stable 293T cell lines were transiently transfected with expression vectors 
for 3xFLAG-DYRK1A and its mutants, and processed as described above. The levels of bound proteins 
were almost the same (within ± 4.0%) between samples (Supporting Figure S2).
The luminescence signal of nanoKAZ-HSP90β in the 3xFLAG-DYRK1A-bound well was almost the 
same as EGFP (luminescence caused by non-specific binding of nanoKAZ-HSP90β) (Fig.  3c). On the 
other hand, significant interactions of nanoKAZ-HSP90β with the DYRK1A mutants were detected com-
pared with EGFP (Fig. 3c). The mutants of K188R and Y319F/Y321F interacted with nanoKAZ-HSP90β 
10- and 3.8-fold more strongly than intact DYRK1A, respectively (Fig.  3c). These results demon-
strate that CDC37-nanoKAZ functions as the interaction reporter with higher signal/noise ratio than 
nanoKAZ-HSP90β .
Interaction between DYRK1A (Y319F/Y321F) and CDC37-nanoKAZ is antagonized by inhibi-
tors of DYRK1A. To examine whether small molecule inhibitors of DYRK1A antagonize the CDC37 
interaction with DYRK1A, we used the substituted mutant of 3xFLAG-DYRK1A (Y319F/Y321F) with 
higher luminescence, but not the K188R mutant because several DYRK1A inhibitors utilize Lys188 in the 
ATP-binding pocket5. The stable cell lines were transfected with the expression vector of 3xFLAG-DYRK1A 
(Y319F/Y321F), and cultured for two days in a 96-well plate. The cells were then treated with the indi-
cated concentrations of small molecules for one hour. Cell lysates were added to FLAG antibody-coated 
96-well plates and luminescence intensities were measured. The amount of bound 3xFLAG-DYRK1A was 
measured using a HRP-conjugated antibody against FLAG. The relative Imax for CDC37-nanoKAZ was 
normalized using the amount of bound protein.
Treatment of the cells with harmine, an inhibitor of DYRK1A5,23–26, decreased the relative lumi-
nescence intensity with a half maximal effective concentration (EC50) of 647 nM (Fig.  4a), indicating 
that harmine antagonizes the interaction of CDC37-nanoKAZ with 3xFLAG-DYRK1A in living cells. 
Another DYRK1A inhibitor, INDY5, also decreased the relative luminescence intensity with an EC50 of 
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1.5 μ M (Fig. 4b), and a broad-spectrum protein kinase inhibitor, staurosporine, decreased the intensity 
with an EC50 of 333 nM (Fig. 4c). In addition to kinase inhibitors, treatment with ganetespib, a HSP90 
inhibitor, decreased the intensity with an EC50 of 14 nM (Fig. 4d), indicating that HSP90 inhibition also 
antagonizes the interaction of CDC37-nanoKAZ with 3xFLAG-DYRK1A (Y319F/Y321F). These small 
molecules did not inhibit the luminescence activity of CDC37-nanoKAZ (Supporting Figure S3). These 
results demonstrate that a cell-based reporter system based on a DYRK1A mutant and CDC37-nanoKAZ 
is available for evaluation of the effects of small molecules on the DYRK1A/CDC37 interaction in living 
cells.
Evaluation of inhibitors of DYRK1A in a synthetic chemical library. The bioluminescent reporter 
system based on CDC37-nanoKAZ was used for evaluation of a library of compounds. Cells expressing 
CDC37-nanoKAZ and 3xFLAG-DYRK1A (Y319F/Y321F) were treated with small molecules and pro-
cessed as described above. The relative luminescence intensities are shown in Fig. 5a. The compound that 
decreased the luminescence intensity to the lowest level was (Z)-5-[(2,3-dihydrobenzofuran-5-yl)methyl-
ene]-2-iminothiazolidin-4-one (referred to as CaNDY: CDC37 association inhibitor for DYRK1A). The 
structure of CaNDY is shown in Fig.  5b. Treatment of the cells with CaNDY decreased the lumines-
cence intensity with an EC50 of 409 nM (Fig.  5c). CaNDY did not inhibit the luminescence activity of 
CDC37-nanoKAZ (Supporting Figure S4).
To examine whether CaNDY inhibits the catalytic activity of DYRK1A, we performed an in vitro 
kinase assay using recombinant DYRK1A and a substrate peptide. In this assay, CaNDY inhibited sub-
strate phosphorylation with a half-maximal inhibitory concentration (IC50) of 7.9 nM (Fig. 5d), whereas 
staurosporine and INDY had IC50 values of 5.4 and 122 nM, respectively. We also examined whether 
CaNDY is an ATP-competitive inhibitor. The double-reciprocal plots showed first-order inhibitory kinet-
ics, demonstrating that CaNDY competed with ATP on a single site of DYRK1A (Fig. 5e). These results 
demonstrate that CaNDY is the ATP-competitive type I inhibitor that antagonizes the CDC37 interaction 
with DYRK1A.
Next we investigated structural requirement for the unique inhibitory effect of CaNDY. We selected 
three small molecules, PD0439, RD0440, and PD0442, from the library, which are structurally similar 
to CaNDY (Fig.  6a). PD0439, which the dihydrobenzofuran structure of CaNDY was replaced with 
methylenedioxybenzene, inhibited the in vitro kinase activity of DYRK1A with IC50 value of 16.7 nM 
Figure 3. Interaction of DYRK1A with nanoKAZ-HSP90β. (a) Structure of the nanoKAZ-HSP90β 
protein. (b) Expression of nanoKAZ-HSP90β protein in transfected 293T cells. nanoKAZ-HSP90β was 
detected with antibodies against nanoKAZ. GAPDH was detected as an internal control. (c) Interactions 
of intact and mutated DYRK1A proteins with nanoKAZ-HSP90β . Luminescence intensities of nanoKAZ-
HSP90β associated with 3xFLAG-DYRK1A proteins are shown as fold-changes relative to that with EGFP. 
Bar graphs show means ± SD, *p < 0.05 (n = 4).
www.nature.com/scientificreports/
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(Fig. 6b). RD0440 and PD0442 with indole substructure showed weak inhibitory activity against recom-
binant DYRK1A, compared with CaNDY and PD0439 (Fig. 6b). These results indicate that oxygen atom 
attached to the benzene and iminothiazolidinone of CaNDY and PD0439 are key pharmacophores for 
exhibiting strong inhibitory effect. Consistently, PD0439 antagonized the CDC37-nanoKAZ interaction 
with 3xFLAG-DYRK1A (Y319F/Y321F) with EC50 value of 573 nM (Fig. 6c). On the other hand, RD0440 
and PD0442 did not antagonize the interaction (Fig.  6c). These results indicate that the interactions 
detected by CDC37-nanoKAZ reflect the potencies of DYRK1A inhibition in vitro, and that weak inhib-
itors of DYRK1A do not antagonize the CDC37 interaction.
CaNDY is a potent and selective inhibitor of DYRK family kinases. We investigated whether 
CaNDY destabilizes DYRK1A as ganetespib does. In the same experiment as Fig. 1, CaNDY decreased 
the 3xFLAG-DYRK1A level compared with the DMSO control (Fig.  7a). Next we examined whether 
CaNDY decreased endogenous DYRK1A protein. HEK293 cells were cultured for 0–4 days with CaNDY 
(2 μ M) and then subjected to SDS-PAGE followed by Western blot analysis using antibodies against 
DYRK1A and GAPDH. Expression of DYRK1A increased during the 4-days culture, and CaNDY pre-
vented accumulation of endogenous DYRK1A (Fig. 7b and Supporting Figure S5), whereas ganetespib 
also prevented it (Supporting Figure S5). The treated cells were also subjected to reverse transcription 
followed by quantitative PCR analysis. Expression of mRNA coding for DYRK1A was slightly decreased 
Figure 4. DYRK1A inhibitors and a HSP90 inhibitor antagonize the interaction of CDC37-nanoKAZ 
with a DYRK1A mutant . (a-d) 293T cells stably expressing CDC37-nanoKAZ were transiently transfected 
with an expression vector for 3xFLAG-DYRK1A (Y319F/Y321F) and then treated with the indicated 
concentrations of harmine (a), INDY (b), staurosporine (c), and ganetespib (d). Luminescence intensities 
are shown as fold-changes relative to that at 0 nM, normalized to the amount of 3xFLAG-DYRK1A (Y319F/
Y321F) bound on a 96-well plate. Points are means ± SD (n = 3). Representative dose-response curves with 
Hill slopes are shown.
www.nature.com/scientificreports/
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by CaNDY (Supporting Figure S6), but this decrease was not significant compared with the reduc-
tion of endogenous DYRK1A protein. Treatment with a proteasome inhibitor partially prevented the 
CaNDY-mediated reduction of 3xFLAG-DYRK1A (Supporting Figure S7), suggesting that proteasome 
is involved in the degradation of DYRK1A. Furthermore, CaNDY did not decrease pre-accumulated 
DYRK1A in an experiment using cycloheximide (Supporting Figure S8). These results suggest that 
CaNDY selectively destabilizes newly synthesized DYRK1A.
To check selectivity of CaNDY for other kinases, we first examined protein expression of several 
kinases in HEK293 cells treated with CaNDY (2 μ M) for 4 days. CaNDY did not decrease the other 19 
kinases (Fig.  7b). Second, in vitro inhibitory activities of 1 μ M CaNDY against a panel of 275 recom-
binant kinases were assessed. CaNDY inhibited DYRK1A, DYRK1B, CLK1, CLK2, and Haspin by over 
90% (Fig. 7c, Supporting Figure S9a, and Supporting Table S1). The in vitro IC50 of CaNDY for DYRK1B 
was 24.1 nM, compared with 2.36 nM for staurosporine and 69.1 nM for INDY (Supporting Figure S9b). 
Third, protein expression of these kinases targeted by CaNDY (DYRK1A, DYRK1B, CLK1, and Haspin) 
was reassessed by Western blot analysis as performed in Fig.  7b. CaNDY also decreased expression of 
the target kinases, but did not decrease CK2α , which was inhibited by 65% in the kinase panel assay 
(Fig.  7d). These results demonstrate that CaNDY is a potent and selective inhibitor of DYRK family 
kinases.
Figure 5. Identification of a potent inhibitor of DYRK1A . (a) A total of 253 compounds from our 
original synthetic chemical library were examined. These compounds were used at 4 μ M. Relative 
luminescence intensities are shown. Harmine was used as a positive control and is indicated by the black 
point. The red point indicates CaNDY. (b) Structure of CaNDY. (c) CaNDY antagonized the interaction 
between DYRK1A and CDC37 complex. 293T cells expressing CDC37-nanoKAZ were transiently 
transfected with an expression vector for 3xFLAG-DYRK1A (Y319F/Y321F) and then treated with the 
indicated concentrations of CaNDY. The points represent means ± SD (n = 3). Representative dose-
response curves with Hill slopes are shown. (d) CaNDY inhibited the catalytic activity of DYRK1A in an 
in vitro kinase assay. Recombinant DYRK1A was incubated with the substrate peptide DYRKtide-F in the 
presence of the indicated concentrations of small molecules. CaNDY, INDY, and staurosporine inhibited the 
kinase activity with IC50 values of 7.9 nM, 122 nM, and 5.4 nM, respectively. Representative dose-response 
curves with Hill slopes are shown. (e) Double-reciprocal plots showing the competitive inhibition of ATP 
by CaNDY. DYRK1A kinase activity was measured at the indicated concentrations of CaNDY and ATP. 
Reciprocal velocity was plotted versus 1/[ATP]. Km = 14.1 μ M and Ki = 1.92 nM.
www.nature.com/scientificreports/
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Discussion
We developed the bioluminescent reporter assay for evaluation of DYRK1A inhibitors, based on the 
interaction of CDC37-nanoKAZ with the DYRK1A Y319F/Y321F mutant. Using this assay, we identified 
a potent inhibitor of DYRK1A in our chemical library. This finding indicates that this reporter assay 
could contribute to chemical screen as well as the evaluation of pre-existing inhibitors.
This study revealed that DYRK1A is a client kinase of the CDC37/HSP90 system. The interaction site 
for CDC37 on client kinases was localized to the N-lobe of the catalytic domain 27–30. Phage display and 
liquid chromatography-tandem mass spectrometry identified a canonical glycine-rich loop (GXGXXG) 
in the N-lobe as a CDC37-interacting motif31. DYRK1A possesses this conserved loop (166GKGSFG171) 
in the N-lobe (Fig. 2d), consistent with our findings.
The requirement of the HSP90 activity in production of DYRK1A suggests that DYRK1A interacts 
with the CDC37/HSP90 system during its maturation process. Our study revealed that DYRK1A is a weak 
client kinase. Thus, CDC37 may be released from DYRK1A after its maturation. Autophosphorylation 
occurs during maturation process19,32,33, indicating a possibility that autophosphorylation of several res-
idues, such as Tyr159, is required for the dissociation step. Interestingly, the results indicate the impor-
tance of Tyr159, which is the autophosphorylation site closest to the consensus CDC37 binding site. 
DYRK1A changes its substrate from a tyrosine to a serine/threonine during the maturation process19. 
In the initial step after synthesis, DYRK1A autophosphorylates its tyrosine residues, and then phospho-
rylates serine/threonine residues of itself and of substrates17,19,21. Thus, Tyr159 autophosphorylation may 
occur in the initial step, leading to the hypothesis that CDC37 transiently interacts with the immature 
tyrosine kinase form of DYRK1A. Chaperones assist folding of newly synthesized proteins and dissociate 
once the proteins are folded34. Several reports suggest that the CDC37 function is specific to immature 
and inactive forms of kinases8,35, and CDC37 plays a pivotal role in the kinome by protecting nascent 
chains from degradation during or immediately after translation8. These reports support the possibility 
described above.
CaNDY and ganetespib affect the complex of DYRK1A and the CDC37/HSP90 chaperone system. The 
treatment of the cells with ganetespib for 8 h prevented accumulation of the DYRK1A protein, suggesting 
that the HSP90 activity is necessary to accumulate the DYRK1A protein. It has been demonstrated that 
Figure 6. Structural requirement of CaNDY. (a) Structures of PD0439, RD0440, and PD0442. (b) In vitro 
kinase assay using these small molecules, as performed in Fig. 5d. (c) CDC37-nanoKAZ binding assay using 
these small molecules, as performed in Fig. 5c.
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CDC37 is required for the interaction between its client kinase and HSP906–9. Thus, antagonistic effect of 
CaNDY against the CDC37 interaction probably causes degradation of DYRK1A during its maturation 
process.
The bioluminescent reporter system has following beneficial points for chemical screening. First, high 
signal/noise ratio: we used nanoKAZ for our reporter system, which is the mutated 19-kDa component 
of Oplophorus luciferase16. Compared with 36-kDa Renilla luciferase, this small luciferase nanoKAZ 
Figure 7. CaNDY induces selective degradation of DYRK1A. (a) 293T cells were transiently transfected 
with an expression vector for 3xFLAG-DYRK1A. At 24 h after transfection, the cells were treated with 
CaNDY (2 μ M) and collected 0 and 8 h after treatment. (b) HEK293 cells were cultured in the presence of 
CaNDY (2 μ M) for four days. The indicated kinases and GAPDH were detected by Western blot analysis 
using antibodies against each protein. The standard classification of these kinases37 is shown. (c) Map of 
the inhibitory activities of CaNDY on a kinase dendrogram37. Percentage inhibitions by 1 μ M CaNDY were 
measured for a panel of 275 kinases. Red circles indicate inhibited kinases and the circle size indicates the 
percentage inhibition. Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.
com). (d) Protein expression of the kinases inhibited by over 90% in (c) and CK2α , which was inhibited by 
65%, was detected by Western blot analysis using antibodies against each protein.
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enables us to make fusion proteins without affecting the function of the fusion partner. This may con-
tribute to the high signal/noise ratio of the CDC37-nanoKAZ interaction. In addition, nanoKAZ has 
strong luminescence. nanoKAZ showed only 1.4-fold strong luminescence compared with Renilla lucif-
erase in in vitro assay using recombinant proteins16; but, nanoKAZ was codon-optimized by preferred 
human codon-optimized method15, which resulted in over 30-fold stronger luminescence intensity of 
nanoKAZ than that of Renilla luciferase in mammalian cells15. The strong luminescence permits accu-
rate and reproducible measurements of the CDC37-nanoKAZ interaction. Second, we used kinase-dead 
mutants in our reporter assay. Transient overexpression of a kinase in a living cell affects the cellular 
signaling cascades, resulting in excessive proliferation or cell death, whereas transient overexpression 
of a dead kinase should be less influential to the cells, leading to reliable results. Moreover, our method 
would contribute to identification of not only type I inhibitor such as CaNDY but also type II inhibitor 
that targets ATP-binding pocket of inactive form. We note that the bioluminescence screening system 
can also identify inhibitors of HSP90 and irreversible inhibitors of nanoKAZ as hit compounds. These 
small molecules should be omitted by appropriate secondary screening.
Using the luminescence reporter system, we identified CaNDY as the ATP-competitive strong inhibi-
tor of DYRK family kinases. In addition to the in vitro inhibitory activity, CaNDY destabilized DYRK1A 
in living cells, which may be due to the antagonistic effect of CaNDY against the interaction between 
DYRK1A and CDC37. CaNDY decreases DYRK1A molecules in cells, thus would efficiently suppresses 
the DYRK1A activity, compared with simple inhibition of the kinase activity.
Our results suggest that CDC37/HSP90 interacts with some client kinases only when the clients are 
immature or inactive. It is unclear how many kinases interact with CDC37/HSP90 when mutated to 
inactive forms, but our approach should be applicable for almost all kinases that possess the conserved 
CDC37 binding site. Kinases are the largest subset of druggable targets, with approximately 2% of all 
genes encoding kinases that regulate cellular signaling pathways involved in a wide range of diseases. 
Thus, we believe that the method presented here is an innovative tool that could be adapted to other 
kinases of interest for drug discovery.
Methods
Materials. Small molecules (CaNDY, PD0439, RD0440, and PD0442) were prepared as described in 
the Supporting Information. INDY was prepared as described previously5. Ganetespib, harmine, and 
staurosporine were purchased from MedChem Express (Princeton, NJ, USA), Tokyo Chemical Industry 
(Tokyo, Japan), and Tocris Bioscience (Bristol, UK), respectively. These compounds were dissolved in 
DMSO (Hybri-MAXTM, Sigma-Aldrich, St. Louis, MO, USA). Puromycin was obtained from Nacalai 
Tesque (Kyoto, Japan) and dissolved in PBS. bis-Coelenterazine (BlueSyn C) was purchased from 
Synchem (Altenburg, Germany) and dissolved in ethanol, after which the solution was divided into ali-
quots and lyophilized. Epoxomicin, a proteasome inhibitor, was obtained from Peptide Institute (Osaka, 
Japan). Cycloheximide was purchased from Sigma-Aldrich.
Antibodies. A rabbit polyclonal antibody against the 19-kDa component of Oplophorus luciferase 
was kindly provided by Dr. Satoshi Inouye (Yokohama Research Center, JNC Corporation, Yokohama, 
Japan). Mouse monoclonal anti-FLAG peptide (clone M2) and horseradish peroxidase-conjugated anti-
bodies were purchased from Sigma-Aldrich. Mouse monoclonal antibodies against SRPK1, SRPK2 (23/
SRPK2), and CDK9 (D-7) were purchased from Pharmingen (BD Biosciences, San Jose, CA, USA), BD 
Transduction Laboratories (BD Biosciences), and Santa Cruz Biotechnology (Santa Cruz, CA, USA), 
respectively. Mouse monoclonal antibody against GAPDH (6C5) and rabbit polyclonal antibodies against 
CLK1 and Haspin were obtained from Abcam (Cambridge, UK). Rabbit monoclonal antibodies against 
CDC37 (D11A3), GSK3β (27C10), AKT1 (C73H10), MEK1 (30C8), SRC (32G6) and rabbit polyclonal 
antibodies against DYRK1A, DYRK1B, p42/p44 MAPK (ERK1/2), p38 MAPK, SAPK/JNK, p70S6K, 
CHK2, MARK3, CK1, CK2α , RAF1, FAK, FYN, c-ABL, and IKKα were purchased from Cell Signaling 
Technology (Beverly, MA, USA). These commercially available 1st antibodies and its reference numbers 
are listed in Table S2. HRP-linked anti-rabbit and anti-mouse IgG were purchased from GE Healthcare 
Life Sciences (Pittsburgh, PA, USA) and Abcam, respectively.
Vector construction. A PCR-amplified fragment of the codon-optimized gene for nanoKAZ 
(GeneBank Accession No. AB823628)15 was fused in-frame to the carboxyl terminus of that of the 
CDC37 gene and to the amino-terminus of that of HSP90β (HSP90AB1 gene product). The fused 
CDC37-nanoKAZ and nanoKAZ-HSP90AB1 gene fragments were subcloned into a pCAGIPuro vector 
using an In-Fusion® HD Cloning kit (Clontech, Takara Bio, Shiga, Japan). The nanoKAZ gene was also 
subcloned into the pCAGIPuro vector. The pCAGIPuro vector, an IRES-based bicistronic expression 
vector in which the gene of interest and a puromycin resistant gene are expressed from a single mRNA, 
enables almost all of the cells selected with puromycin to express the gene product.
Expression vectors for DYRKs and DYRK1A mutants were constructed in a pcDNA5/FRT/TO vector 
(Life Technologies, Thermo Fisher Scientific) (Kii et al. manuscript in revision). In brief, PCR-amplified 
fragments of 3xFLAG-tagged DYRKs were fused in-frame to the amino-terminus of EGFP via the 
F2A peptide sequence by overlap-extension PCR, and the combined fragments were inserted into the 
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pcDNA5/FRT/TO vector. The EGFP gene was also inserted into the pcDNA5/FRT/TO vector. The recon-
stituted vector sequences are available upon request.
Cell culture and transfection. 293T and HEK293 cells were maintained in low glucose Dulbecco’s 
modified Eagle’s medium (Nacalai Tesque) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 
100 units/mL penicillin and 100 μ g/mL streptomycin (Nacalai Tesque). Cells were transfected with plas-
mid DNAs using polyethylenimine ‘MAX’ (Polysciences, Warrington, PA, USA) and then selected with 
Puromycin (Nacalai Tesque) for pCAGIPuro vectors to establish stable cell lines.
Western blot analysis. Western blot analysis was performed using the antibodies described above. 
In brief, total cell lysates were separated by SDS-PAGE (5–20% gels; ATTO, Tokyo, Japan) under reduc-
ing conditions and then transferred to a PVDF membrane (PALL, SP, Brazil). Antibody reactions were 
performed with Can Get Signal® Immunoreaction Enhancer Solution (Toyobo). Peroxidase activities 
on the membrane were visualized with ECL Western Blotting Detection Reagents (GE Healthcare) or 
ImmunoStar® LD (Wako Pure Chemical Industries, Osaka, Japan), and a ChemiDocTM MP Imaging 
System (Bio-Rad, Hercules, CA, USA).
Reverse transcription and quantitative PCR analysis. Total RNA of the cells was isolated using 
Sepasol-RNA I Super G (Nacalai Tesque), and then subjected to reverse transcription with Prime Script 
RTase (Takara Bio). Realtime PCR was performed with FastStart Universal SYBR Green Master (Rox) 
(Roche Diagnostics, Basel, Switzerland) using StepOnePlus Real-Time PCR System (Applied Biosystems, 
Life technologies). The nucleotide sequences of the primers are as follows: the forward primer for 
DYRK1A, 5′ -GACCAAAGATGGAAAACGGGA-3′ ; the reverse primer for DYRK1A, 5′ -CCTCCTGT 
TTCCACTCCAAGAA-3′ ; the forward primer for GAPDH, 5′ -ACGGATTTGGTCGTATTGGG-3′ ; and 
the reverse primer for GAPDH, 5′ -GTAGTTGAGGTCAATGAAGGGGTC-3′ .
ELISA of the CDC37-nanoKAZ interaction. Stable cell lines transfected with expression vectors 
for 3xFLAG-tagged DYRK family kinases and its mutants were lysed in ice-cold HENG buffer (50 mM 
HEPES-KOH, pH 7.9, 150 mM NaCl, 20 mM Na2MoO4, 2 mM EDTA, 5% Glycerol, 0.5% TritonX-100) 
containing protease inhibitor cocktail (Nacalai Tesque) on ice. The cleared lysates were added to 96-well 
plates (OptiPlate-96 HB; PerkinElmer, Waltham, MA, USA) coated with antibody against FLAG peptide 
(clone M2) diluted in sodium bicarbonate buffer (pH 9.6), and incubated at 4 °C for 3 h. The wells were 
wash three times with ice-cold HENG buffer and then a luminescence assay was performed.
The luminescence activity of the cell lysates was determined using a Centro LB 960 Microplate 
Luminometer (Berthold Technologies, Bad Wildbad, Germany). A reaction mixture containing 
bis-coelenterazine (final concentration of 0.1–1 μ g/100 μ L) in PBS containing 0.02% Tween20 and 20 mM 
EDTA was injected. The luminescence intensity was recorded at 0.1 s intervals for 10 s or 10 min. The 
maximum luminescence intensity (Imax), represented in relative luminescence units (rlu), was used in 
the study.
After measuring the luminescence intensities, the wells were washed three times with HENG buffer, 
and incubated with HRP-conjugated anti-FLAG antibody diluted with PBS containing 5% Tween20 
and 2% fetal bovine serum at 37 °C for one hour. After extensive washing, TMD Super Sensitive One 
Component HRP Microwell Substrate (SurModics, Eden Prairie, MN, USA) was added into the well 
and the reaction was stopped with sulfuric acid. Absorbance at 450 nm was measured with ARVO X5 
(PerkinElmer). The relative amount of protein bound on the well was estimated from the absorbance.
In Supporting Figure S1a, the values of Imax are shown in kinetics plots. In Figs 2c,e, 3c, S1d, S3, and 
S4, the relative luminescence intensities are shown as the fold-change in the Imax values of the samples 
relative to Imax with EGFP. In Figs 4, 5a,c and 6c, the relative luminescence intensities were normalized 
to the amount of the bound 3xFLAG-DYRK1A mutant and calculated as the fold-change relative to the 
value at 0 μ M of the compounds. Nonspecific binding of CDC37-nanoKAZ to the well did not need 
to be taken into account because the background luminescence caused by nonspecific binding (EGFP 
sample) was small compared with the luminescence intensities of the 3xFLAG-DYRK family kinases and 
its mutants (Figs 2c,e, 3c and S1d).
Small molecules in our original synthetic chemical library, including unpublished small molecule 
inhibitors of DYRK1A and its structural derivatives (data not shown), were added to the 96-well plates 
containing the transfected cells at a final concentration of 4 μ M. The cells were then processed as 
described above.
In vitro kinase assay. Detailed information on the assay conditions is available on the website of 
Carna Biosciences (http://www.carnabio.com/english/index.html; Kobe, Japan). In brief, full-length 
human recombinant kinases were expressed using a baculovirus expression system as amino-terminal 
GST-fusion proteins, and purified by glutathione-Sepharose chromatography. The GenBank accession 
numbers of DYRK1A, DYRK1B, DYRK2, and DYRK3 were NP_001387.2, NP_004705.1, NP_003574.1, 
and NP_003573.2. Kinase activities were evaluated by Off-chip Mobility Shift Assay after reaction of 1 μ M 
of the substrate DYRKtide-F with ATP (25 μ M for DYRK1A, 50 μ M for DYRK1B, 10 μ M for DYRK2, 
and 5 μ M for DYRK3). For each compound, a DMSO solution was diluted in assay buffer to yield a final 
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concentration of 1% DMSO. After incubation for one hour at room temperature, substrate phosphoryl-
ation was analyzed by electrophoretic separation of the substrate and products using a Caliper LC3000 
platform (Caliper Life Sciences, Mountain View, CA, USA). The phosphorylated product (P)/(P + sub-
strate) ratio was calculated at each concentration of each small molecule and the percent inhibition was 
expressed relative to a control assay in the absence of the small molecule. Staurosporine was used as a 
reference inhibitor in each kinase assay. The IC50 of each compound was calculated by interpolation on 
a log-concentration-response curve fitted with a four-parameter logistic equation.
The effects of 1 μ M CaNDY against 275 kinases (listed in Supporting Table S1) were tested using the 
QuickScout screening assist Mobility Shift Assay or with an immobilized metal ion affinity-based fluores-
cence polarization screening express kit with an ATP concentration at the Km or 1 mM. All kinase assays 
were carried out at Carna Biosciences. The inhibitory map was made with Kinome Render36.
ATP kinetics assay. The kinase reaction for ATP kinetics was performed in a reaction mixture con-
taining serially diluted inhibitors, 10 mM MOPS-KOH (pH 7.0), 10 mM magnesium acetate, 200 μ M 
EDTA, 2.5–40 μ M ATP, 0.125–0.4 μ Ci [γ -32P]ATP, 5 μ M DYRKtide (Anaspec, CA, USA), and 1 nM of 
GST-tagged human DYRK1A (Cat# PV3785, Life Technologies), for a final volume of 25 μ l. The final 
concentration of DMSO was adjusted to 0.1%, regardless of the inhibitor concentration. The reaction 
mixture was incubated at 30 °C for 15 min, and phosphoric acid (final 5%) was then added to stop 
the reaction. 25 μ L of the reaction mixture was dispensed onto P81, a phosphocellulose membrane 
(Whatman, GE Healthcare), and washed four times in 5% phosphoric acid. Cherenkov light from the 
incorporated 32P was measured using a liquid scintillation counter. The kinase assay conditions, including 
the incubation period and the concentration of the kinases and substrates, were optimized to maintain 
linearity during the incubation. The net radioactivity was determined by subtracting the background 
count from the reaction mixture without kinase. The amount of incorporated 32P was calculated from 
the standard line. The Km and Ki values were calculated with Prism6 software (GraphPad Software, San 
Diego, CA, USA) using the competitive inhibition model.
Statistical analysis. Statistical analysis of experimental data was performed by Mann-Whitney test. 
Results are shown as means ± SD with p values (*p < 0.05, **p < 0.01, ***p < 0.001). Data were fitted to 
a four-parameter logistic curve (variable slope) for Hill slope determination, from which IC50 and EC50 
values were calculated, using Prism 6.0.
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